期刊文献+

冠心病患者1次介入治疗全部完成3支血管血运重建的安全性和有效性 被引量:1

Safety and efficacy of one percutaneous coronary intervention for three coronary arteries in patients with three-vessel coronary disease
下载PDF
导出
摘要 目的:观察对冠状动脉3支血管病变患者1次全部完成3支血管血运重建的安全性和有效性。方法:2010年1月~2012年9月连续对在我科住院的52例3支血管病变患者1次介入治疗全部完成3支血管的血运重建。对该组患者的临床资料、影像资料、介入治疗情况进行总结分析;对所有患者进行院内随访和平均32个月的临床随访,观察主要心血管不良事件的发生情况。结果:52例患者均1次经皮冠状动脉介入(PCI)术全部完成3支血管的血运重建,成功率100%。共处理靶血管156支,靶病变195个,每例3—6(3.6±0.9)个病变。Syntax积分为15—32(21±4)分,其中,≤22分38例,占73%(38/52);23—32分14例,占27%(14/52)。随访20~52(32±9)个月,主要终点事件的发生率为2%(1/52);次级终点事件的发生率为6%(3/52)。结论:经有选择的冠心病3支血管病变患者1次完成3支血管的PCI,是可行的,有较好的安全性和有效性。 AIM: To evaluate the safety and effect of one percutaneous coronary intervention (PCI) for three coronary arteries in patients with three-vessel coronary disease. METHODS: According to the inclusion criteria, 52 consecutive patients with three-vessel coronary disease between January 2010 and September 2012 were enrolled in this study. Three coronary arteries were completely treated by one PCI in all patients. Follow-up was conducted in all patients and major adverse cardiac events (MACE: cardiogenic death, myocardial infarction, and repeated revascularization) were calculated. RESULTS: One-time PCI was conducted in 52 patients with 195 target lesions and 156 target vessels treated by PCI, and the success rate was 100%. Mean Syntax Score of the 52 patients was 21. At 32 _+ 9 months, the rate of MACE was 2% (1/52) and the secondary point events rate was 6% (3/52). CONCLUSION: One PCI for three coronary arteries is fairly safe and effective in patients with three-vessel coronary disease.
出处 《心脏杂志》 CAS 2015年第3期283-286,共4页 Chinese Heart Journal
关键词 经皮冠状动脉腔内介入治疗 三支血管病变 SYNTAX积分 Percutaneous coronary intervention three-vessel coronary disease
  • 相关文献

参考文献16

  • 1中国经皮冠状动脉介入治疗指南2012(简本)[J].中华心血管病杂志,2012,40(4):271-277. 被引量:424
  • 2Task Force on the Management of ST-segment Elevation Acute Myo- cardial Infarction of the European Society of Cardiology ( ESC ), Steg PG, James SK, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[ J]. Eur Heart J, 2012, 33(20) :2569 -2619.
  • 3经皮冠状动脉介入治疗指南(2009)[J].中华心血管病杂志,2009,37(1):4-25. 被引量:544
  • 4Daemen J, Kuck KH, Macaya C, et al. Muhivessel coronary revas- cularlzation in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-Ⅱ ( Arterial Revascularization Therapies Study-Part Ⅱ) trlal[J]. JAm Coil Cardiol, 2008, 52(24) :1957 -1967.
  • 5Hannan EL, Wu C, Walford G, et al. Dmg-eluting stents vs coro- nary-artery bypass grafting in multivessel coronary disease [ J ]. N Engl J Med, 2008, 355(4) :331 -341.
  • 6Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coro- nary intervention versus coronary-artery bypass grafting for severe coronary artery disease[J]. N Engl J Med, 2009, 360(10) :961 - 972.
  • 7Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of coro- nary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYN- TAX trial[J]. Eur Heart J, 2011, 32(17) :2125 -2134.
  • 8Tamburino C, Angioliilo DJ, Capranzano P, et al. Complete versus incomplete revascularization in patients with multivessel disease un- dergoing pereutaneous coronary intervention with drug-eluting stents [ J ]. Catheter Cardiovasc Interv, 2008, 72 (4) :448 - 456.
  • 9Nikolsky E, Gruberg L, Patil CV, et al. Percutaneous coronary interventions in diabetic patients: is complete revascularization im- portant? [J]. J Invazive Cardiol, 2004, 16(3) :102 - 106.
  • 10Hannah EL, Samadashvili Z, Wafford G, et al. Culprit vessel per- cutaneous coronary intervention versus muhivessel and staged percu- taneous coronary intervention for ST-segment elevation myocardial infarction patients with muhivessel disease [ J ]. JACC Cardiovasc Interv, 2010, 3(1) :22 -31.

二级参考文献20

  • 1CHANCE研究组.无保护左主干病变支架置入术预后及影响因素的分析——中国无保护左主干病变支架置入术注册(CHANCE)研究[J].中华心血管病杂志,2005,33(3):210-215. 被引量:19
  • 2Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿(译),David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志(中文版),2007,26(3):131-139. 被引量:59
  • 3Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery ( EACTS ), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J,2010 , 31:2501-2555.
  • 4Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation, 2011, 124 :e574-651.
  • 5Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coil Cardiol, 2011,58 :e123-210.
  • 6Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation ( EuroSCORE ). Eur J Cardiothorac Surg, 1999,16:9-13.
  • 7Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009,360:961- 972.
  • 8Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coil Cardiol,2010,55:1923-1932.
  • 9Online STS fish calculator [ S/OL]. [ 2012-01-01 ]. http:// riskcalc, sts. org/STSWebRiskCalc273/de, aspx.
  • 10Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes ( CURRENT-OASIS 7 ): a randomised factorial trial. Lancet,2010,376 : 1233-1243.

共引文献954

同被引文献4

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部